JP2020512368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512368A5 JP2020512368A5 JP2019553442A JP2019553442A JP2020512368A5 JP 2020512368 A5 JP2020512368 A5 JP 2020512368A5 JP 2019553442 A JP2019553442 A JP 2019553442A JP 2019553442 A JP2019553442 A JP 2019553442A JP 2020512368 A5 JP2020512368 A5 JP 2020512368A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- composition according
- synuclein
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000539 amino acid group Chemical group 0.000 claims description 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 36
- 208000018737 Parkinson disease Diseases 0.000 claims description 24
- 208000032859 Synucleinopathies Diseases 0.000 claims description 18
- 230000008021 deposition Effects 0.000 claims description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 201000002832 Lewy body dementia Diseases 0.000 claims description 12
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 12
- 230000002159 abnormal effect Effects 0.000 claims description 12
- 238000009825 accumulation Methods 0.000 claims description 12
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 12
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 12
- 210000003169 central nervous system Anatomy 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 10
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 9
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 9
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 9
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 9
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 9
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 9
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 9
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 210000004558 lewy body Anatomy 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 3
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000019355 Synuclein Human genes 0.000 claims 18
- 108050006783 Synuclein Proteins 0.000 claims 18
- 238000005303 weighing Methods 0.000 claims 5
- 230000003442 weekly effect Effects 0.000 claims 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 55
- 230000037396 body weight Effects 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479818P | 2017-03-31 | 2017-03-31 | |
| US62/479,818 | 2017-03-31 | ||
| US201762528790P | 2017-07-05 | 2017-07-05 | |
| US62/528,790 | 2017-07-05 | ||
| PCT/IB2018/052236 WO2018178950A1 (en) | 2017-03-31 | 2018-03-30 | Compositions and methods for treating synucleinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512368A JP2020512368A (ja) | 2020-04-23 |
| JP2020512368A5 true JP2020512368A5 (enExample) | 2021-05-06 |
Family
ID=62092178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553442A Withdrawn JP2020512368A (ja) | 2017-03-31 | 2018-03-30 | シヌクレイノパチーを治療するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200377579A1 (enExample) |
| EP (1) | EP3630815A1 (enExample) |
| JP (1) | JP2020512368A (enExample) |
| KR (1) | KR20200026789A (enExample) |
| CN (1) | CN110997715A (enExample) |
| AU (1) | AU2018242626A1 (enExample) |
| BR (1) | BR112019020335A2 (enExample) |
| CA (1) | CA3058304A1 (enExample) |
| IL (1) | IL269637A (enExample) |
| JO (1) | JOP20190227A1 (enExample) |
| MA (1) | MA48730A (enExample) |
| SG (1) | SG11201908672WA (enExample) |
| WO (1) | WO2018178950A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2746778C (en) | 2008-12-19 | 2019-04-23 | University Of Zurich | Human anti-alpha-synuclein autoantibodies |
| EP3583124A1 (en) | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| WO2019064053A1 (en) * | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES |
| USRE50630E1 (en) | 2017-10-31 | 2025-10-14 | Creative BioPeptides, Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| BR112021006123A2 (pt) * | 2018-10-19 | 2021-07-20 | Janssen Vaccines & Prevention B.V. | anticorpos anti-sinucleína |
| AU2020394842A1 (en) * | 2019-12-04 | 2022-06-30 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
| US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
| JP2023541048A (ja) | 2020-09-10 | 2023-09-27 | プロシーナ バイオサイエンシーズ リミテッド | パーキンソン病の処置 |
| CN117915952A (zh) | 2021-09-16 | 2024-04-19 | H.隆德贝克有限公司 | 用于治疗突触核蛋白病的组合物和方法 |
| CN120882734A (zh) * | 2023-02-06 | 2025-10-31 | 创新生物肽有限公司 | 用于治疗神经紊乱的肽 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| CA2746778C (en) * | 2008-12-19 | 2019-04-23 | University Of Zurich | Human anti-alpha-synuclein autoantibodies |
| SI2723379T1 (sl) * | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| UA118441C2 (uk) * | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
-
2017
- 2017-06-16 JO JOP/2019/0227A patent/JOP20190227A1/ar unknown
-
2018
- 2018-03-30 AU AU2018242626A patent/AU2018242626A1/en not_active Abandoned
- 2018-03-30 SG SG11201908672W patent/SG11201908672WA/en unknown
- 2018-03-30 US US16/497,055 patent/US20200377579A1/en not_active Abandoned
- 2018-03-30 BR BR112019020335A patent/BR112019020335A2/pt not_active IP Right Cessation
- 2018-03-30 JP JP2019553442A patent/JP2020512368A/ja not_active Withdrawn
- 2018-03-30 MA MA048730A patent/MA48730A/fr unknown
- 2018-03-30 KR KR1020197030675A patent/KR20200026789A/ko not_active Abandoned
- 2018-03-30 EP EP18721459.8A patent/EP3630815A1/en not_active Withdrawn
- 2018-03-30 CN CN201880026858.1A patent/CN110997715A/zh active Pending
- 2018-03-30 WO PCT/IB2018/052236 patent/WO2018178950A1/en not_active Ceased
- 2018-03-30 CA CA3058304A patent/CA3058304A1/en active Pending
-
2019
- 2019-09-25 IL IL26963719A patent/IL269637A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512368A5 (enExample) | ||
| JP7504664B2 (ja) | 二重特異性抗体 | |
| JP7725185B2 (ja) | 抗ｔｒｅｍ２抗体及びその使用方法 | |
| JP2023029882A (ja) | 抗ｔｒｅｍ２抗体及びその使用方法 | |
| JP2020141669A5 (enExample) | ||
| EP1853310B1 (en) | Anti a beta antibody formulation | |
| JP2020503260A5 (enExample) | ||
| JP2019517540A5 (enExample) | ||
| CA3030662C (en) | New indications for anti-il-1-beta therapy | |
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| JP2019527194A5 (enExample) | ||
| CN114558129A (zh) | 用于降低心血管风险的方法 | |
| CN114173816A (zh) | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 | |
| HK1244229A1 (zh) | 治疗CROHN病的整联蛋白β7拮抗剂和方法 | |
| Faissner et al. | Efficacy and safety of multiple sclerosis drugs approved since 2018 and future developments | |
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| JP2019503706A5 (enExample) | ||
| HK1249016A1 (zh) | 使用抗il-34抗体治疗神经疾病的组合物和方法 | |
| US20220213188A1 (en) | Methods of treating neurodegenerative diseases | |
| JP2020527152A5 (enExample) | ||
| JP2019532970A5 (enExample) | ||
| JP2020505350A5 (enExample) | ||
| US20230287133A1 (en) | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab | |
| CA3199806A1 (en) | Methods of reducing tau in human subjects | |
| S. Rommer et al. | Monoclonal antibodies in the treatment of neuroimmunological diseases |